| Literature DB >> 34822496 |
Tianjian Tong1, Xiaoyang Liu2, Chenxu Yu1.
Abstract
This review aims to provide an informative summary of studies on extraction and nanoencapsulation of phlorotannins to improve their bioavailability and bioactivity. The origin, structure, and different types of phlorotannins were briefly discussed, and the extraction/purification/characterization methods for phlorotannins were reviewed, with a focus on techniques to improve the bioactivities and bioavailability of phlorotannins via nano-sized delivery systems. Phlorotannins are promising natural polyphenol compounds that have displayed high bioactivities in several areas: anticancer, anti-inflammation, anti-HIV, antidiabetic, and antioxidant. This review aims to provide a useful reference for researchers working on developing better utilization strategies for phlorotannins as pharmaceuticals, therapeuticals, and functional food supplements.Entities:
Keywords: bioactivity; bioavailability; nano delivery systems; phlorotannins
Mesh:
Substances:
Year: 2021 PMID: 34822496 PMCID: PMC8622035 DOI: 10.3390/md19110625
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Six basic types of phlorotannin in brown algae.
| Type of Phlorotannin | Basic Linkage | Representative Structural Formula |
|---|---|---|
| Fucols | aryl–aryl linkages |
|
| Fucophlorethols | aryl–aryl and aryl–ether |
|
| Fuhalols | aryl–ether linkages, OH groups in every third ring |
|
| Carmalols | dibenzodioxin linkages |
|
| Phlorethols | aryl–ether linkages |
|
| Eckols | a dibenzodioxin element substituted by a phenoxyl group at C-4 |
|
Figure 1Factors affecting polyphenols therapeutic applications, replicated from Conte et al. [65] with permission.
Figure 2Schematic representation of nano-sized delivery systems, replicated from Qi et al. [71] with permission.
Examples of reported anti-inflammatory effects of phlorotannins.
| Compounds | Origin | Anti-Inflammation Effects | Test System | Dosage * | Reference |
|---|---|---|---|---|---|
| Phlorotannins extraction | Suppress H2O2-induced damage to cells. | RAW 264.7 cells | 2.5–80 μg/mL | [ | |
| Phloroglucinol |
| Suppress tumor necrosis factor-α, interleukin-1β, interleukin-6, and prostaglandin E2 produced by lipopolysaccharide. | HT1080 cells | 1, 5, 10 μM. | [ |
| Suppress matrix metalloproteinase express to reduce chronic inflammation. | RAW264.7 cells | 1, 5, 10 μM. | |||
| Phloroglucinol and dieckol |
| Suppress binding of IgE and FcɛRI. | KU812 cells | 12.5, 25, 50, 100 μM | [ |
| Phlorolfucofuroeckol |
| Suppress iNOS and COX-2 gene’s expression. | RAW 264.7 cells | 20 μM | [ |
* Blank was used as negative control in all the cited research.
Anti-HIV bioactivities of phloroglucinol and phlorotannins.
| Compounds | Origin | Anti-HIV Effects | Test System | Dosage * | Reference |
|---|---|---|---|---|---|
| 6,6′-bieckol |
| Suppress HIV-1 (human immunodeficiency virus type 1) induced syncytia formation, production of vrial p24 antigen, effects of lytic. | C8166 and CEM-SS cells | 0.5, 2.5, 5, 25, 50, 250, 500 μM | [ |
| Arzanol (phloroglucinol α-pyrone) | Suppress NF-κB and replication of HIV-1. | human T lymphocyte cell (Jurkat cell) | 5, 10, 25 μM | [ | |
| Mallotophenone, mallotojaponin and mallotochromene |
| Mallotophenone can suppress HIV-reverse transcriptase. | (rA)n.(dT)12–18 as primers | 10 μg/mL | [ |
| Synthesized dimeric phloroglucinols | N/A | Suppress HIV-1 NL4.3 virus in vitro. | Human CD4+ T cell line (CEM-GFP) | 20 μg/reaction | [ |
| Prenylated phloroglucinols |
| Suppress replication of HIV-1. | RDDP assay | 3.5–8 μM | [ |
* Blank was used as negative control in all the cited research.
Antidiabetes functionality of phlorotannins.
| Compounds | Origin | Antidiabetic Activities | Test System | Dosage * | Reference |
|---|---|---|---|---|---|
| Dieckol |
| Suppress α-glucosidase. | Recombinant Human Aldo-keto Reductase rhAKR1B10 | 10 μM | [ |
| 6,6′-Bieckol |
| Suppress PTP 1B. | Same as above | 10 μM | [ |
| 7-Phloroeckol |
| Suppress ACE and α-glucosidase. | Same as above | 10 μM | [ |
| 2-phloroeckol |
| Suppresss α-glucosidase and PTP 1B. | Same as above and | 10 μM. | [ |
| α-amylase, α-glucosidase, glucose induced protein glycation and glucose diffusion through dialysis membrane | 133.33 µg/mL | ||||
| Phlorofucofuroeckol-A |
| Suppress α-glucosidase, PTP 1B, ACE, AGEs, and Aldose reductase. | pNPP substrate | 25 and 10 mM | [ |
| AGE assay | 200, 100, 50 mg/mL | ||||
| α-amylase, α-glucosidase, glucose-induced protein glycation and glucose diffusion through dialysis membrane | 133.33 µg/mL | ||||
| Phloroglucinol, Eckol, Dieckol, and Phlorofucofuroeckol |
| All can suppress α-glucosidase | Recombinant Human Aldo-keto Reductase | 10 μM | [ |
* Blank was used as negative control in all the cited research.
Antioxidant effects (including photo-oxidative stresses) of phlorotannins.
| Compounds | Origin | Antioxidant Effects | Test System | Dosage * | Reference |
|---|---|---|---|---|---|
| Dieckol |
| Suppress UAB radiation induced photo-oxidative stress. | Human fibroblaste cell | 5, 50, 250 μM. | [ |
| Suppress UV-B radiation induced cell damages (both DNA damage and nuclear fragmentation). | Human fibroblaste cell | 5, 50, 250 μM. | |||
| Diphlorethohydroxycarmalol (DPHC) | Brown algae. | DPHC can scavenge UV-B radiation induced ROS; with more DPHC added into the treatment, cell viability was uplifted. | Human fibroblast cells | 5, 50, 250 μM. | [ |
| Dieckol |
| Suppress cell damage induced by UV-B radiation in vitro. | HaCaT cells | 5, 50, 100, and 250 μM. | [ |
| Phlorotannin extract (PE) |
| Suppress levels of ROS and NO induced by UV-B radiation. In addition, cell death rate can be reduced by pre-treating zebra fish embryos with PE. | Zebra fish | 5, 50, 100, and 250 μM. | [ |
| Diphlorethohydroxycarmalol (DPHC) |
| Suppress high glucose-induced oxidative stress. | Human umbilical vein endothelial cells | 5, 25, and 50 μM. | [ |
| Suppress high glucose induced inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and activation of nuclear factor-kappa B (NF-κB) activation. | Human umbilical vein endothelial cells | 5, 25, and 50 μM. |
* Blank was used as negative control in all the cited research.
Figure 3Surface, three-dimensional AFM images, and depth distribution of MCP nanofibers (a–c) and PT/MCP nanofibers (d–f). Replicated from Cui et al. [67] with permission.
Figure 4Transmission electron microscopy (TEM) image of phlorotannin@PVP nanoparticles (PPNPS). The concentration of PPNPS was 1 mg/mL, replicated from Qi et al. [66] with permission.
Figure 5Release profile of free phlorotannin and Phlorotannin@PVP nanoparticles (PPNPS) (1:8, w/w) in simulated gastrointestinal fluids, replicated from Qi et al. [66] with permission.
Figure 6Annexin/PI staining of: (A) untreated HeLa cells; (B) HeLa cells treated with 250 μg/mL of E. cava extracts; (C) HeLa cells treated with 250 μg/mL of biosynthesized AgNPs; and (D) relative cell population of HeLa cells after treatment with E. cava extracts and biosynthesized AgNPs. Replicated from Shim et al. [69] with permission.